Non-viral gene therapy for spinal cord regeneration

Spinal cord injuries lead to permanent disabilities due to neuron loss and scar tissue. Gene therapy aims to introduce genes into cells at the injury site, causing them to produce therapeutic molecules that promote tissue repair. Non-viral gene vectors are a safer alternative to viral vectors for gene therapy. They can carry larger DNA sequences and be modified to target specific cell types. Nanocarriers improve gene delivery efficiency into cells. Biomaterial scaffolds can provide structural support for tissue regeneration and act as reservoirs for sustained gene delivery.

• 1
  Non-viral gene vectors can transfect endogenous cells in the injured spinal cord, leading to the production of therapeutic molecules and long-lasting biological effects.
• 2
  Nanocarriers have improved neural cell transfection efficiency in vitro, enhancing the delivery of therapeutic genes to glial cells and neurons.
• 3
  Combining biomaterial scaffolds with gene vectors can provide structural guidance for regeneration and sustained gene delivery, improving axonal regrowth and functional recovery after spinal cord injury.